Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18764806 | 0.92 | L3MBTL1 (0.55) | L3MBTL1MEN1GAAKMT2ATDP1 | |
| SCHEMBL16199411 | 0.88 | MEN1 (0.43) | L3MBTL1MEN1GAAKMT2ATDP1 | |
| SCHEMBL21068290 | 0.87 | L3MBTL1 (0.49) | L3MBTL1MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL16245608 | 0.86 | TDP1 (0.44) | MEN1GAAKMT2ATDP1STK17B | |
| SCHEMBL21281607 | 0.86 | KDM4E (0.45) | L3MBTL1MEN1GAAKMT2ATDP1 | |
| SCHEMBL22012670 | 0.86 | TDP1 (0.47) | MEN1GAAKMT2ATDP1STK17B | |
| SCHEMBL22366404 | 0.85 | TDP1 (0.46) | MEN1GAAKMT2ATDP1STK17B | |
| SCHEMBL19027486 | 0.84 | DRD2 (0.45) | MEN1GAAKMT2ATDP1STK17B | |
| SCHEMBL31627058 | 0.84 | TDP1 (0.44) | MEN1GAAKMT2ATDP1STK17B | |
| SCHEMBL16245563 | 0.82 | TDP1 (0.47) | MEN1GAAKMT2ATDP1STK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171014-B | Monocyclolactam compounds and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-112771040-B | Monocyclic lactam compounds and uses thereof | 南京圣和药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-110167933-B | As αVAzole amides and amines as integrin inhibitors | 百时美施贵宝公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3538527-B1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3538527-B1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3882246-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3538527-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089358-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089358-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | ITGAV, ITGB1, ITGA1 | L3MBTL1 3897/4885MEN1 642/4885GAA 2836/4885 |
| US-20220002288-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | BPGM, IL1B, WEE1 | L3MBTL1 2374/4885MEN1 707/4885GAA 1883/4885 |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | L3MBTL1 3897/4885MEN1 642/4885GAA 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.